Galecto Inc (GLTO)
0.6751
-0.02
(-3.57%)
USD |
NASDAQ |
May 10, 16:00
0.6751
0.00 (0.00%)
After-Hours: 20:00
Galecto Cash from Financing (TTM): 2.853M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.853M |
| December 31, 2023 | 2.876M |
| September 30, 2023 | 2.941M |
| June 30, 2023 | 3.194M |
| March 31, 2023 | 0.53M |
| December 31, 2022 | 0.507M |
| September 30, 2022 | 0.442M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.018M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 91.79M |
| June 30, 2021 | 147.72M |
| March 31, 2021 | 147.72M |
| December 31, 2020 | 187.39M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
Dec 2021
187.39M
Maximum
Dec 2020
42.00M
Average
2.864M
Median
Cash from Financing (TTM) Benchmarks
| Novo Nordisk A/S | -10.04B |
| Genmab A/S | -86.53M |
| Ascendis Pharma A/S | 166.15M |
| Evaxion Biotech AS | -- |
| IO Biotech Inc | 71.86M |